TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19791825

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All new biological agents
Number of subjects: 0
Study: 17092348

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1479
Study: 15237126

Group type: EXPERIMENTAL
Intervention: Medial-lateral pin fixation
Number of subjects: 66

Group type: COMPARATOR
Intervention: 2-lateral pin fixation
Number of subjects: 66
Study: 11316024

Group type: EXPERIMENTAL
Intervention: LASIK custom treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: LASIK conventional treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparative group (one eye custom LASIK and the other eye conventional LASIK)
Number of subjects: 38
Study: 9397101

Group type: EXPERIMENTAL
Intervention: Misoprostol tablets (n = 234)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Misoprostol gel (n = 233)
Number of subjects: 467
Study: 8248841

Group type: EXPERIMENTAL
Intervention: Radiation therapy with wedge filter (group B)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Radiation therapy without wedge filter (group A)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Radiation therapy with wedge filter for large T1a lesions (group B)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Radiation therapy without wedge filter for large T1a lesions (group A)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Minor chronic complications in group A
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Minor chronic complications in group B
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Arytenoid edema in group B
Number of subjects: 244
Study: 2884191

Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29901444

Group type: EXPERIMENTAL
Intervention: BioFreedom stent (BFS)
Number of subjects: 104
Study: 27576775

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 14112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14112

Group type: COMPARATOR
Intervention: More intensive antiplatelet therapy (meta-analysis across 4 trials)
Number of subjects: 14112
Study: 25127372

Group type: EXPERIMENTAL
Intervention: Active Online Learning (AOL)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Passive Online Learning (POL)
Number of subjects: 214
Study: 22484638

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg daily for 7 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Curcumin (50 muM) in vitro
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Curcumin (50 muM) pretreatment
Number of subjects: 33
Study: 20845811

Group type: EXPERIMENTAL
Intervention: Panitumumab (single-agent treatment)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Cetuximab (single-agent treatment)
Number of subjects: 1
Study: 18953247

Group type: EXPERIMENTAL
Intervention: Ulinastatin (100,000 U)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 15892486

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (5 globules in a potency of 200c given at 12h interval during ICU stay)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (5 globules at 12h interval during ICU stay)
Number of subjects: 70
Study: 12151927

Group type: EXPERIMENTAL
Intervention: Epidural blockade with local anesthetic
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (general anesthesia alone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both anesthetic techniques
Number of subjects: 16
Study: 9915448

Group type: EXPERIMENTAL
Intervention: L-arginine (1,500 mg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 7776995

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy with INR between 2.0 and 3.9
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy with INR below 2.0
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy with INR of 5.0 or above
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Target INR of 3.0
Number of subjects: 214
Study: 2333695

Group type: EXPERIMENTAL
Intervention: High dose penicillin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Bilirubin level
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Urine to plasma urea ratio
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 88
Study: 24061

Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluphenazine enanthate
Number of subjects: 32
Study: 31955428

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) with one hidden layer, 10 nodes, and 10 input features
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) trained with IMRT fields
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Analytic method
Number of subjects: 1071
Study: 31496678

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol combination therapy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Tiotropium monotherapy
Number of subjects: 131
Study: 27737566

Group type: EXPERIMENTAL
Intervention: Professional Boundaries for Health Professionals (PBHP) training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no training initially)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Experimental group (PBHP training)
Number of subjects: 36
Study: 26363637

Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg weekly for up to 24 months)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Azithromycin (adherence ≥70%)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 391
Study: 23910580

Group type: EXPERIMENTAL
Intervention: Level 1 intervention (information to a pharmacist on facility guideline concordance)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Level 2 intervention (information to a pharmacist and a list of patients not meeting guideline goals)
Number of subjects: 220
Study: 21775554

Group type: EXPERIMENTAL
Intervention: 85% ED (tripled vegetable content)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 75% ED (quadrupled vegetable content)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100% ED (standard condition)
Number of subjects: 40
Study: 19846149

Group type: EXPERIMENTAL
Intervention: Doxazosin (0.03 mg/kg daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ibuprofen (control)
Number of subjects: 39
Study: 17110825

Group type: EXPERIMENTAL
Intervention: Methylphenidate (OROS MPH, Concerta) 18‐54 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14740125

Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5‐fluorouracil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional administration of leucovorin or levamisole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with new drugs (capecitabine, UFT, irinotecan, oxaliplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy for elderly patients
Number of subjects: 0
Study: 11375842

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with 1:200,000 epinephrine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isotonic sodium chloride (placebo)
Number of subjects: 90
Study: 10980874

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study: 8674405

Group type: EXPERIMENTAL
Intervention: 500 mg daily of tauroursodeoxycholic acid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1000 mg daily of tauroursodeoxycholic acid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1500 mg daily of tauroursodeoxycholic acid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diarrhea
Number of subjects: 24
Study: 1455418

Group type: EXPERIMENTAL
Intervention: Induced hypertension chemotherapy (IHC) with 5‐fluorouracil, adriamycin, and mitomycin C
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-induced hypertension chemotherapy (same regimen without hypertension)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Induced hypertension chemotherapy (IHC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Correlation between clinical and histological ratings
Number of subjects: 13
Study: 6732937

Group type: EXPERIMENTAL
Intervention: Hydralazine (apressine) 50-100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Endralazine (mirethilan) 5-15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prazosine (pratsiol) 2-5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (obsidan) 80-120 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30031891

Group type: EXPERIMENTAL
Intervention: Virtual Tilted Room (VTR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Body-Weight Support Walking (BWSW)
Number of subjects: 20
Study: 27112842

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH; 100 μg IV)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG; 4000 IU IM)
Number of subjects: 68
Study: 25041868

Group type: EXPERIMENTAL
Intervention: Intensive intonation‐based speech therapy for 15 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensive intonation‐based speech therapy
Number of subjects: 20
Study: 22460943

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg wafer
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 21239359

Group type: EXPERIMENTAL
Intervention: Abacavir 300 mg twice daily
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 18051003

Group type: EXPERIMENTAL
Intervention: Seal&Protect (Dentsply DeTrey GmbH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vivasens (Ivoclar Vivadent AG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BisBlock (BISCO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 60
Study: 15618784

Group type: EXPERIMENTAL
Intervention: 0.56 mg/kg succinylcholine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study: 12406534

Group type: EXPERIMENTAL
Intervention: Verum+COT
Number of subjects: 186

Group type: COMPARATOR
Intervention: Sham+COT
Number of subjects: 186

Group type: COMPARATOR
Intervention: nil+COT
Number of subjects: 186
Study: 10588598

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg plus continuing inhaled beclomethasone
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo tablet plus continuing inhaled beclomethasone
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg and inhaled placebo
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo tablet and inhaled placebo
Number of subjects: 642
Study: 8546171

Group type: EXPERIMENTAL
Intervention: Ketoconazole (100 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no ketoconazole)
Number of subjects: 100
Study: 2401123

Group type: EXPERIMENTAL
Intervention: Oral propafenone (300 to 450 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (35 to 50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-propafenone (additive effect observed)
Number of subjects: 8
Study: 31429383

Group type: EXPERIMENTAL
Intervention: Stabilization splint worn by 23 patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: No intervention (follow-up without any intervention) for remaining subjects
Number of subjects: 46
Study: 30471384

Group type: EXPERIMENTAL
Intervention: HIIE (10 × 1 min at 100% Vmax, 1 min recovery)
Number of subjects: 15

Group type: COMPARATOR
Intervention: MICE (20 min at 55–59% VO2reserve)
Number of subjects: 15
Study: 30121808

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with paclitaxel plus bevacizumab (2×4 cycles)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Continuous treatment with paclitaxel plus bevacizumab (8 cycles)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with paclitaxel plus bevacizumab
Number of subjects: 420

Group type: COMPARATOR
Intervention: Continuous treatment with paclitaxel plus bevacizumab
Number of subjects: 420
Study: 26761213

Group type: EXPERIMENTAL
Intervention: Cisplatin with pemetrexed and concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin with vinorelbine and concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT)
Number of subjects: 0
Study: 25261187

Group type: EXPERIMENTAL
Intervention: Virtual reality training as an adjunct to conventional therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dose-matched conventional training
Number of subjects: 0
Study: 22296075

Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 21054824

Group type: EXPERIMENTAL
Intervention: Proton radiation therapy (72 Gy E ± 5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbon ion radiation therapy (63 Gy E ± 5%)
Number of subjects: 0
Study: 18762135

Group type: COMPARATOR
Intervention: Logo of the Netherlands Asthma Foundation
Number of subjects: 1938

Group type: COMPARATOR
Intervention: Senior signature (director and professor)
Number of subjects: 1938
Study: 16272621

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15189616

Group type: EXPERIMENTAL
Intervention: High anger feedback with projection allowed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dishonesty feedback with projection allowed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low anger feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dishonesty feedback
Number of subjects: 0
Study: 10331117

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8913468

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 2 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 4 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (all doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1905451

Group type: EXPERIMENTAL
Intervention: 6.25 mg irtemazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12.5 mg irtemazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25 mg irtemazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 37.5 mg irtemazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: irtemazole
Number of subjects: 12
Study: 6132891

Group type: EXPERIMENTAL
Intervention: pindolol (15 mg daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: acebutolol (500 mg daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: acebutolol (500 mg daily) after 16 months
Number of subjects: 11
Study: 31260419

Group type: EXPERIMENTAL
Intervention: TOTAL (whole-body split training routine with muscle groups trained 5 days per week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SPLIT (muscle groups trained once per week)
Number of subjects: 18
Study: 27510655

Group type: EXPERIMENTAL
Intervention: Colonic administration of 13C-labelled acetate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Colonic administration of 13C-labelled propionate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Colonic administration of 13C-labelled butyrate
Number of subjects: 12
Study: 26717861

Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25mg, twice daily during the run-in period
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 24980672

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg once daily (n=9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ramipril 5 mg once daily (n=7)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatments (Aliskiren and Ramipril)
Number of subjects: 16
Study: 22271261

Group type: EXPERIMENTAL
Intervention: Functional networks during seizures
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pre-seizure changes in network properties
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dynamic interactions of epileptic activities with the network
Number of subjects: 3
Study: 18987057

Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Low-dose infusion (LDI)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: High-dose bupivacaine (Control)
Number of subjects: 1054
Study: 17891199

Group type: EXPERIMENTAL
Intervention: SLT after ALT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: SLT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ALT
Number of subjects: 96
Study: 14871429

Group type: EXPERIMENTAL
Intervention: CsA trough levels measured at day 2 posttransplant
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: CsA trough levels lower than 300 ng/mL
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: CsA trough values
Number of subjects: 334

Group type: COMPARATOR
Intervention: C2 levels considered alone
Number of subjects: 334
Study: 12238832

Group type: EXPERIMENTAL
Intervention: 10 mg/kg tranexamic acid (TA) followed by infusion of 1 mg/kg per hour during the operation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 50
Study: 9589246

Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 8
Study: 7977174

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg p.o. 1 hour prior to chemotherapy, repeated after 6 and 12 hours plus dexamethasone 20 mg i.v. 40 minutes prior to chemotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: High-dose metoclopramide, dexamethasone, and orphenadrine (Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg PO t.i.d. days 2 and 3
Number of subjects: 64

Group type: COMPARATOR
Intervention: Metoclopramide 0.5 mg/kg p.o. q.i.d. and dexamethasone 8 mg i.m. b.i.d. days 2 and 3 (Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ondex
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 2683904

Group type: EXPERIMENTAL
Intervention: Intermittent external negative pressure ventilation (ENPV) with the Emerson Pulmowrap ventilator during a 3-week in-hospital pulmonary rehabilitation program (Group II)
Number of subjects: 16

Group type: COMPARATOR
Intervention: In-hospital pulmonary rehabilitation program without ENPV (Group I)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 16
Study: 31676898

Group type: EXPERIMENTAL
Intervention: Community-to-clinic navigator intervention
Number of subjects: 345

Group type: COMPARATOR
Intervention: Group education (comparison group)
Number of subjects: 345
Study: 28071929

Group type: EXPERIMENTAL
Intervention: SMART (n = 18)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Fit Brains® (n = 19)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait-list group (n = 16)
Number of subjects: 53
Study: 27316489

Group type: EXPERIMENTAL
Intervention: 50mg/kg of magnesium sulfate (MS) in 100ml 0.9% NaCl solution over 20min before anesthesia induction (Group A)
Number of subjects: 600

Group type: COMPARATOR
Intervention: 100ml 0.9% NaCl solution (Group B)
Number of subjects: 600
Study: 26353411

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg day(-1))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22625877

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg every 12 h for 4 days with a single 15 mg dose of pioglitazone on day 3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pioglitazone alone (15 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gemfibrozil with pioglitazone
Number of subjects: 30
Study: 21130476

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting
Number of subjects: 894

Group type: COMPARATOR
Intervention: Open vein harvesting
Number of subjects: 894
Study: 18841790

Group type: EXPERIMENTAL
Intervention: CRSwNP group (n=10)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 10
Study: 15905227

Group type: EXPERIMENTAL
Intervention: Oral protein preload plus ID saline perfusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral protein preload plus ID fat perfusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water preload plus ID saline perfusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water preload plus ID fat perfusion
Number of subjects: 20
Study: 11895545

Group type: EXPERIMENTAL
Intervention: 0.01% P‐113 mouthrinse
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: 0.03% P‐113 mouthrinse
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 294
Study: 10399449

Group type: EXPERIMENTAL
Intervention: ICU group (preoperative treatment aiming at a CI >= 4.0 l/min/m2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no special treatment)
Number of subjects: 31
Study: 7551323

Group type: EXPERIMENTAL
Intervention: rIL-2 (12 x 10(6) IU/m2/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study: 2076441

Group type: EXPERIMENTAL
Intervention: Vancomycin (4 drops of a 5% solution every 8 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no local treatment)
Number of subjects: 40